Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06532799

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer (BAH250)

Efficacy and Safety of Autologous Tumor-Infiltrating Lymphocytes (TIL) Therapy Combined With Pembrolizumab (Keytruda) Immunotherapy in Patients With Advanced or Metastatic Refractory Stomach and Esophageal Cancer

Sponsor: Essen Biotech

Conditions Esophageal Cancer Esophageal Cancer Metastatic to Bone Esophageal Cancer Metastatic to Liver Esophageal Cancer Metastatic to Lung Stomach Cancer Stomach Cancer Recurrent Stomach Cancer, Adenocarcinoma

Interventions Cyclophosphamid Fludarabine Interleukin-2 Pembrolizumab Tumor Infiltrating Lymphocytes (TIL)

Updated 4 times since 2024 Last updated: Nov 10, 2024 Started: Sep 10, 2024 Primary completion: Dec 15, 2025 Completion: Dec 28, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06532799, this PHASE1/PHASE2 trial focuses on Esophageal Cancer and Esophageal Cancer Metastatic to Bone and remains actively recruiting participants. Sponsored by Essen Biotech, it has been updated 4 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Dec 2024 — Present [monthly]

Recruiting PHASE1/PHASE2
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Nov 2024 [monthly]

Not Yet Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1/PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Essen Biotech

Data source: Essen Biotech

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China